

Dasatinib

Recent Results in Cancer Research

201, 27-65

DOI: [10.1007/978-3-642-54490-3_2](https://doi.org/10.1007/978-3-642-54490-3_2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors. <i>ChemMedChem</i> , 2015, 10, 2027-2041.	1.6	13
2	A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer. <i>PLoS ONE</i> , 2015, 10, e0144126.	1.1	36
3	The role of dasatinib in the management of chronic myeloid leukemia. <i>Drug Design, Development and Therapy</i> , 2015, 9, 773.	2.0	52
4	Severe thrombocytopenia after dasatinib treatment in a patient with Philadelphia chromosome-positive chronic myeloid leukemia. <i>OncoTargets and Therapy</i> , 2015, 8, 955.	1.0	2
5	Current treatment options in patients with mastocytosis: status in 2015 and future perspectives. <i>European Journal of Haematology</i> , 2015, 94, 474-490.	1.1	64
6	Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients. <i>Annals of Hematology</i> , 2015, 94, 133-140.	0.8	26
7	Epigenetic-based therapy: From single- to multi-target approaches. <i>International Journal of Biochemistry and Cell Biology</i> , 2015, 69, 121-131.	1.2	40
8	Best Practices in Chronic Myeloid Leukemia Monitoring and Management. <i>Oncologist</i> , 2016, 21, 626-633.	1.9	40
9	Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. <i>Cancer</i> , 2016, 122, 1398-1407.	2.0	47
10	The Biology and Pathogenesis of Chronic Myeloid Leukemia. <i>Hematologic Malignancies</i> , 2016, , 17-39.	0.2	8
11	Novel investigational therapies for treating biliary tract carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1423-1436.	1.9	5
12	Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 4-31.	1.4	40
13	Dasatinib first-line: Multicentric Italian experience outside clinical trials. <i>Leukemia Research</i> , 2016, 40, 24-29.	0.4	6
14	Melasma treatment: A novel approach using a topical agent that contains an anti-estrogen and a vascular endothelial growth factor inhibitor. <i>Medical Hypotheses</i> , 2017, 101, 1-5.	0.8	20
15	Dasatinib inhibits actin fiber reorganization and promotes endothelial cell permeability through RhoA-ROCK pathway. <i>Cancer Medicine</i> , 2017, 6, 809-818.	1.3	38
16	NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib. <i>International Journal of Hematology</i> , 2017, 106, 666-674.	0.7	21
17	Phosphorylation of the C-Raf N Region Promotes Raf Dimerization. <i>Molecular and Cellular Biology</i> , 2017, 37, .	1.1	20
18	Quantitative proteomics reveal the anti-tumour mechanism of the carbohydrate recognition domain of Galectin-3 in Hepatocellular carcinoma. <i>Scientific Reports</i> , 2017, 7, 5189.	1.6	15

#	ARTICLE	IF	CITATIONS
19	Assessment of soluble cytotoxic T lymphocyte-associated antigen-4, transforming growth factor β , and platelet-derived microparticles during dasatinib therapy for patients with chronic myelogenous leukemia. <i>Journal of Blood Medicine</i> , 2019, Volume 10, 1-8.	0.7	4
20	Characterization and In Vivo Validation of a Three-Dimensional Multi-Cellular Culture Model to Study Heterotypic Interactions in Colorectal Cancer Cell Growth, Invasion and Metastasis. <i>Frontiers in Bioengineering and Biotechnology</i> , 2018, 6, 97.	2.0	30
21	ANXA2 promotes esophageal cancer progression by activating MYC-HIF1A-VEGF axis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 183.	3.5	64
22	The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling. <i>Cell Communication and Signaling</i> , 2018, 16, 21.	2.7	18
23	Dasatinib. <i>Recent Results in Cancer Research</i> , 2018, 212, 29-68.	1.8	48
24	NF- κ B Activation in Lymphoid Malignancies: Genetics, Signaling, and Targeted Therapy. <i>Biomedicines</i> , 2018, 6, 38.	1.4	37
25	The second generation tyrosine kinase inhibitor dasatinib induced eryptosis in human erythrocytes—An in vitro study. <i>Toxicology Letters</i> , 2018, 295, 10-21.	0.4	9
26	Beyond TCR Signaling: Emerging Functions of Lck in Cancer and Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3500.	1.8	88
27	New roles for B cell receptor associated kinases: when the B cell is not the target. <i>Leukemia</i> , 2019, 33, 576-587.	3.3	26
28	Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1360-1372.	3.3	40
29	Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 39-50.	1.9	7
30	Extracellular Vesicle Activation of Latent HIV-1 Is Driven by EV-Associated c-Src and Cellular SRC-1 via the PI3K/AKT/mTOR Pathway. <i>Viruses</i> , 2020, 12, 665.	1.5	15
31	Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India. <i>Annals of Hematology</i> , 2021, 100, 85-96.	0.8	7
32	Inhibitors of Src Family Kinases, Inducible Nitric Oxide Synthase, and NADPH Oxidase as Potential CNS Drug Targets for Neurological Diseases. <i>CNS Drugs</i> , 2021, 35, 1-20.	2.7	23
33	Tyrosine kinase inhibitors protect the salivary gland from radiation damage by increasing DNA double-strand break repair. <i>Journal of Biological Chemistry</i> , 2021, 296, 100401.	1.6	13
34	Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit. <i>Molecular Cancer Research</i> , 2021, 19, 1221-1233.	1.5	3
35	Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer. <i>Pharmaceuticals</i> , 2021, 14, 589.	1.7	32
36	Src/Lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies. , 2021, 9, e002582.		14

#	ARTICLE	IF	CITATIONS
37	Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy. <i>Neurobiology of Disease</i> , 2021, 156, 105410.	2.1	20
38	Peripheral T-Cell Lymphoma, Not Otherwise Specified: Clinical Manifestations, Diagnosis, and Future Treatment. <i>Cancers</i> , 2021, 13, 4535.	1.7	9
39	Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. <i>Journal of Clinical Investigation</i> , 2015, 126, 169-180.	3.9	156
40	MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. <i>Journal of Clinical Investigation</i> , 2017, 127, 4179-4192.	3.9	62
41	Drug conjugated nanoparticles activated by cancer cell specific mRNA. <i>Oncotarget</i> , 2016, 7, 38243-38256.	0.8	17
42	A Chemical Approach to Overcome Tyrosine Kinase Inhibitors Resistance: Learning from Chronic Myeloid Leukemia. <i>Current Medicinal Chemistry</i> , 2019, 26, 6033-6052.	1.2	6
43	2,4,5-Trisubstituted Thiazole: A Privileged Scaffold in Drug Design and Activity Improvement. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 2535-2577.	1.0	9
45	<i>Campylobacter jejuni</i> ssp. <i>jejuni</i> bacteraemia in a patient with BCR-ABL-positive chronic myelogenous leukaemia in remission on dasatinib therapy. <i>JMM Case Reports</i> , 2015, 2, .	1.3	0
46	Receptor Tyrosine Kinase Inhibitors. , 2016, , 3940-3946.		6
47	Î²2-Adrenoceptor Activation Stimulates IL-6 Production via PKA, ERK1/2, Src, and Beta-Arrestin2 Signaling Pathways in Human Bronchial Epithelia. <i>Lung</i> , 2021, 199, 619-627.	1.4	5
49	A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities. <i>Blood Research</i> , 2021, 56, 229-242.	0.5	19
50	Effects of tyrosine kinase inhibitors on androgen, estrogen Î±, glucocorticoid and thyroid receptors. <i>Toxicology and Applied Pharmacology</i> , 2022, 434, 115818.	1.3	2
52	Potential Approaches Versus Approved or Developing Chronic Myeloid Leukemia Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 801779.	1.3	13
53	Nintedanib and Dasatinib Treatments Induce Protective Autophagy as a Potential Resistance Mechanism in MPM Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 852812.	1.8	2
56	The LCK-14-3-3Î¶-TRPM8 axis regulates TRPM8 function/assembly and promotes pancreatic cancer malignancy. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	6
57	Identification of Src Family Kinases as Potential Therapeutic Targets for Chemotherapy-Resistant Triple Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 4220.	1.7	6
58	Macrophages: A rising star in immunotherapy for chronic pancreatitis. <i>Pharmacological Research</i> , 2022, 185, 106508.	3.1	4
59	Suppressing of Srcâ€™s Hic-5â€™s JNKâ€™s AKT Signaling Reduced GAPDH Expression for Preventing the Progression of HuCCT1 Cholangiocarcinoma. <i>Pharmaceutics</i> , 2022, 14, 2698.	2.0	1

#	ARTICLE	IF	CITATIONS
61	Differentially expressed genes in systemic sclerosis: Towards predictive medicine with new molecular tools for clinicians. <i>Autoimmunity Reviews</i> , 2023, 22, 103314.	2.5	5
64	Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies. , 2023, 40, .		1